UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 271

Sortiert nach

1148-P: Cenicriviroc Safety in over 1,200 Subjects

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

1164-P: Effects of Cenicriviroc in Adults with NASH on Inflammatory Cytokines and Metabolic Parameters

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

1839-P: Glycemic Control Impacts Severity of Hepatic Fibrosis in NAFLD/NASH

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Link zum Volltext

Verfügbarkeit prüfen

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S1601-S1602

2019

Link zum Volltext

Verfügbarkeit prüfen

354 - Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1055-S1055

2017

Link zum Volltext

Verfügbarkeit prüfen

357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1085-S-1085

2018

Link zum Volltext

Verfügbarkeit prüfen

358 - Statin Use and Liver Injury in Nonalcoholic Fatty Liver Disease: Results of a Paired Clinical and Gene Expression Profile Analysis

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1085-S-1086

2018

Link zum Volltext

Verfügbarkeit prüfen

451 NEW SAFETY AND EFFICACY ANALYSES FROM THE REGENERATE TRIAL OF OBETICHOLIC ACID FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1250-S-1251

2023

Link zum Volltext

Verfügbarkeit prüfen

753 - Differential DNA Methylation in Whole Blood Reflects that in Liver and Distinguishes Patients with Advanced NAFLD Fibrosis from Those with Normal Histology: A Potential Non-Invasive Tool

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1069-S1070

2017

Link zum Volltext

Verfügbarkeit prüfen

79-Year-Old Woman With Blue Toes

Mayo Clinic proceedings, 1995-03, Vol.70 (3), p.292-295

1995

Link zum Volltext

Verfügbarkeit prüfen

823 Epigenetic Regulation of Gene Expression in NAFLD

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-929-S-929

2012

Link zum Volltext

Verfügbarkeit prüfen

830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

929 Associations of Sleep Duration and Sleep Quality With Clinical and Histologic Features of Nonalcoholic Fatty Liver Disease (NAFLD)

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-931-S-931

2014

Link zum Volltext

Verfügbarkeit prüfen

964 – Branched Chain Amino Acid and Bile Acid Metabolites Associate with Future Clinical Decompensation in Nonalcoholic Fatty Liver Disease

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1223-S-1223

2019

Link zum Volltext

Verfügbarkeit prüfen

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Hepatology (Baltimore, Md.), 2023-05, Vol.77 (5), p.1797-1835

2023

Link zum Volltext

Verfügbarkeit prüfen

ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?

Hepatology (Baltimore, Md.), 2022-08, Vol.76 (2), p.295-297

2022

Link zum Volltext

Verfügbarkeit prüfen

Acute liver failure occurring immediately following anti-d immune globulin infusion in a patient with chronic hepatitis B infection

Digestive diseases and sciences, 2007-04, Vol.52 (4), p.914-919

2007

Link zum Volltext

Verfügbarkeit prüfen

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review

Gastroenterology, 2023-10, Vol.165 (4), p.1080-1088

2023

Link zum Volltext

Verfügbarkeit prüfen

AHRR Hypomethylation mediates the association between maternal smoking and metabolic profiles in children

Hepatology communications, 2023-10, Vol.7 (10)

2023

Link zum Volltext

Verfügbarkeit prüfen

Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study

Journal of hepatology, 2022-07, Vol.77, p.S495

2022

Link zum Volltext

Verfügbarkeit prüfen

Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children

Epigenetics, 2022-11, Vol.17 (11), p.1446-1461

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(264)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Englisch
(271)
Japanisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Life Sciences & Biomedicine
(160)
Humans
(144)
Gastroenterology & Hepatology
(124)
Female
(92)
Male
(83)
Middle Aged
(72)
Adult
(65)
Fibrosis
(59)
Liver - Pathology
(55)
Biopsy
(51)
Liver Diseases
(51)
Hepatology
(46)
Liver
(42)
Fatty Liver
(35)
Non-Alcoholic Fatty Liver Disease - Drug Therapy
(34)
Non-Alcoholic Fatty Liver Disease - Pathology
(33)
Liver Cirrhosis
(31)
Treatment Outcome
(30)
Biological And Medical Sciences
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

1148-P: Cenicriviroc Safety in over 1,200 Subjects

1164-P: Effects of Cenicriviroc in Adults with NASH on Inflammatory Cytokines and Metabolic Parameters

136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis

1839-P: Glycemic Control Impacts Severity of Hepatic Fibrosis in NAFLD/NASH

1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design

354 - Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study

358 - Statin Use and Liver Injury in Nonalcoholic Fatty Liver Disease: Results of a Paired Clinical and Gene Expression Profile Analysis

451 NEW SAFETY AND EFFICACY ANALYSES FROM THE REGENERATE TRIAL OF OBETICHOLIC ACID FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS

753 - Differential DNA Methylation in Whole Blood Reflects that in Liver and Distinguishes Patients with Advanced NAFLD Fibrosis from Those with Normal Histology: A Potential Non-Invasive Tool

79-Year-Old Woman With Blue Toes

823 Epigenetic Regulation of Gene Expression in NAFLD

830-P: The Pan-PPAR Agonist Lanifibranor Improves Nonalcoholic Steatohepatitis (NASH) and Glycemic Control

844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels

929 Associations of Sleep Duration and Sleep Quality With Clinical and Histologic Features of Nonalcoholic Fatty Liver Disease (NAFLD)

964 – Branched Chain Amino Acid and Bile Acid Metabolites Associate with Future Clinical Decompensation in Nonalcoholic Fatty Liver Disease

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?

Acute liver failure occurring immediately following anti-d immune globulin infusion in a patient with chronic hepatitis B infection

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review

AHRR Hypomethylation mediates the association between maternal smoking and metabolic profiles in children

Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study

Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children

Suchergebnisse filtern